Abstracts tagged "Antibodies"

Abstract Number: 390 • 2018 ACR/ARHP Annual Meeting
Severe Axial and Pelvifemoral Muscle Damage in Immune-Mediated Necrotizing Myopathy Evaluated By Whole-Body MRI
Océane Landon-Cardinal¹, Cedi Koumako², Giulia Hardouin³, Benjamin Granger³, Harmen Reyngoudt², Jean-Marc Boisserie², Aude Rigolet¹, Baptiste Hervier¹, Nicolas Champtiaux¹, Perrine Guillaume¹, Mathieu Vautier¹, Pierre Carlier², Olivier Benveniste¹ and Yves Allenbach¹, ¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ²Laboratoire de RMN AIM & CEA, Centre d'Explorations Fonctionnelles, Institut de Myologie, Paris, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) are a severe condition with early muscle damage attested by MRI of thigh muscles. Presence of damage in the other…
Abstract Number: 2801 • 2018 ACR/ARHP Annual Meeting
A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis
Kazuhiko Higashioka¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: A plethora of evidence from genome-wide association studies and relevant animal models implicates a pivotal role of T cells in the pathogenesis of rheumatoid…
Abstract Number: 397 • 2018 ACR/ARHP Annual Meeting
Myositis-Specific Autoantibodies and Their Clinical Associations
Victor Tak Lung Wong¹, Ho So¹, Ricky Wai Ki Ip², Virginia W Lao³, Steve H Pang³, Lai-Shan Tam⁴, Priscilla Wong⁵, Lydia Ho Pui Tam⁶, Tsz On Lam⁷, Mei Yan Law⁸, Isaac CW Yim⁹, Tin Lok LAI¹⁰, Patrick Man Leung Lee¹¹ and Ronald Man Lung Yip¹², ¹Kwong Wah Hospital, Kowloon, Hong Kong, ²Queen Mary Hospital, Hong Kong, Hong Kong, ³Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, ⁵Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ⁶Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Prince of Wales Hospital, New Territories, Hong Kong, ⁸Alice Ho Miu Ling Nethersole Hospital, New Territories, Hong Kong, ⁹Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ¹⁰Medicine, Tseung Kwan O Hospital, Tseung Kwan O, Hong Kong, ¹¹Yan Chai Hospital, Kowloon, Hong Kong, ¹²Tung Wah Group of Hospitals, Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Myositis-specific autoantibodies (MSAs) have been shown to predict clinical features and have prognostic implications in patients with idiopathic inflammatory myopathies (IIMs), with anti-melanoma differentiation-associated…
Abstract Number: 2935 • 2018 ACR/ARHP Annual Meeting
A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
Svetlana I. Nihtyanova¹, Emma C. Derrett-Smith², Carmen Maria Fonseca³, Voon H. Ong² and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Division of Medicine, University College London, London, United Kingdom, ³Department of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: The Le Roy et al. classification of SSc into limited and diffuse cutaneous subtype remains the most commonly used. Nevertheless, autoantibodies are much better…
Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Guro Løvik Goll¹, Nils Bolstad², Ines Iria^3,4, Rolf Klaasen⁵, Kristin Kaasen Jørgensen⁶, Inge C Olsen⁷, Ana Valido⁸, Maria J Saavedra⁹, João E. Fonseca¹⁰, Merete Lorentzen¹¹, Cato Mork¹², Knut EA Lundin¹³, David J Warren¹⁴, Espen A. Haavardsholm¹⁵, Jorgen Jahnsen¹⁶, Tore Kvien¹⁵ and João Gonçalves¹⁷, ¹Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ³Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, ⁴iMed- Research Institute for medicines, Lisbon, Portugal, ⁵Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ⁶Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹¹Dept of Dermatology, Rikshospitalet, Oslo, Norway, ¹²Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ¹³Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, ¹⁴Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ¹⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ¹⁷Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Ana Paula Luppino-Assad¹, Adriana Bortoluzzo², Henrique Carriço da Silva³, Danieli Andrade⁴ and Percival Sampaio-Barros⁴, ¹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, ²c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, ³Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, ⁴Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
Abstract Number: 999 • 2018 ACR/ARHP Annual Meeting
Development of an Affimab Engineered to Simultaneously Target IL-6 and Tnfα for Therapeutic Use in Rheumatoid Arthritis
Kyu-Tae Kim, Jong-Seo Lee and Bong-Kook Ko, AbClon Inc., Seoul, Korea, Republic of (South)
Background/Purpose: Antibodies may be functionalized using Affibody® molecules to create bispecific AffiMabs. We used protein engineering to develop single-construct biologics suitable for blocking inflammation driven…
Abstract Number: 1223 • 2018 ACR/ARHP Annual Meeting
Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis
Caitlyn L. Holmes¹, Chloe Peyton², Amy Bier³, Tobias Donlon², Christie M. Bartels⁴ and Miriam A. Shelef^5,6, ¹University of Wisconsin - Madison, Madison, WI, ²University of Minnesota Medical School, Minneapolis, MN, ³Stritch School of Medicine of Loyola University Chicago, Chicago, IL, ⁴Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, ⁵Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ⁶William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: Patients with rheumatoid arthritis, an autoimmune disease affecting ~1% of the population, have an increased risk of infection. Interestingly, data are mixed for response…
Abstract Number: 1310 • 2018 ACR/ARHP Annual Meeting
Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease
Verónica Wolff¹, Juan Maya², Carolina Cuéllar³, Matías Florenzano¹, Alexis Peralta⁴ and Viviana Balboa⁴, ¹Rheumatic Lung diseases Unit, Instituto Nacional del Tórax, Santiago, Chile, ²Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ³Rheumatology Section, Hospital del Salvador, Universidad de Chile, SANTIAGO, Chile, ⁴Laboratorio Inmunología, Hospital Del Salvador, SANTIAGO, Chile
Background/Purpose: Interstitial Lung Disease (ILD) is a common manifestation of Connective Tissue Diseases (CTD), mainly Systemic sclerosis (SSc), Rheumatoid Arthritis and Idiopathic Inflammatory Myositis (IIM)…
Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Fang Shen¹, Jennifer F. Nemeth², Brian Jones¹, Ann Cai¹, Shannon Hitchcock³, Thai Dinh², Ravi Malaviya¹ and Tatiana Ort¹, ¹Immunology, Janssen R&D, Spring House, PA, ²Janssen Biotech, Janssen R&D, Spring House, PA, ³Immunology, Janssen R&D, Springhouse, PA
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…
Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Ash Maroof¹, Remi Okoye¹, Tim Smallie¹, Dominique Baeten^2,3, Sophie Archer¹, Catherine Simpson¹, Meryn Griffiths¹ and Stevan Shaw¹, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
Abstract Number: 1666 • 2017 ACR/ARHP Annual Meeting
Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations
Yann Becker¹, Renee Claude Loignon¹, Genevieve Marcoux¹, Anne-Sophie Julien², Imene Melki¹, Lihi Eder³, Eric Wagner¹, Martin Pelletier¹, Marie-Josee Hebert⁴, Clemence Belleannee¹, Joyce Rauch⁵, Melanie Dieude⁴, Paul R. Fortin⁶ and Eric Boilard¹, ¹CHU de Quebec and Universite Laval, Quebec City, QC, Canada, ²CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴CHUM and Universite de Montreal, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada
- Background/Purpose: Eukaryotic cells contain organelles called mitochondria that govern energy supply and control of cell death. Whereas damaged organs or activated cells can extrude…
Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
Abstract Number: 2136 • 2017 ACR/ARHP Annual Meeting
Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis
Adam Schiffenbauer¹, Sara Faghihi-Kashani², Terrance P. O'Hanlon¹, Willy Flegel³, Sharon Adams³, Ira N. Targoff⁴, Chester V. Oddis^5,6, Rohit Aggarwal^7,8, Lisa G Rider¹, Steven R. Ytterberg⁹, Lisa Christopher-Stine¹⁰, Sonye K. Danoff¹¹, Paul F. Dellaripa^12,13, Ejaz Shamim¹⁴, Andrew Mammen¹⁵ and Frederick W Miller¹⁶, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ³Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁸Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Rheumatology, Mayo Clinic, Rochester, MN, ¹⁰Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁴9. Department of Neurology, Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, ¹⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ¹⁶Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication and a major contributor to mortality and morbidity in polymyositis and dermatomyositis (PM/DM). Prior studies have…
Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting
Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].